What's Going On With Zimmer Biomet Shares After Q1 Earnings?
What's Going On With Zimmer Biomet Shares After Q1 Earnings?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported first-quarter adjusted earnings per share of $1.94, beating the street view of $1.87.
Zimmer Biomet Holdings, Inc.（纽约证券交易所代码：ZBH）公布的第一季度调整后每股收益为1.94美元，超过了街景的1.87美元。
The company reported quarterly sales of $1.889 billion, beating the analyst consensus of $1.869 billion.
该公司公布的季度销售额为18.89亿美元，超过了分析师共识的18.69亿美元。
Quarterly sales rose 3.2% year over year and 4.4% on a constant currency basis.
季度销售额同比增长3.2％，按固定货币计算增长4.4％。
Geographically, sales within the U.S. grew 3.7% year over year, while international sales rose 2.5%.
从地域上看，美国境内的销售额同比增长3.7％，而国际销售额增长2.5％。
Segment-wise, revenues gained 3.4% in the Knees segment and fell 0.3% in the Hips unit. Sales from Sports Medicine, Extremities, Trauma, Craniomaxillofacial, and Thoracic unit gained 4.4% year over year.
细分市场方面，膝盖板块的收入增长了3.4％，臀部部门的收入下降了0.3％。运动医学、四肢、创伤、颅颌面和胸科的销售额同比增长4.4％。
The company highlighted that it received U.S. Food and Drug Administration 510(k) clearance for the ROSA Shoulder System – the world's first robotic assistant for shoulder replacement surgery- and announced that the first surgery was successfully completed in April at Mayo Clinic.
该公司强调，其全球首款肩部置换手术机器人助手ROSA Shoulder System已获得美国食品药品监督管理局的510（k）许可，并宣布首例手术于4月在梅奥诊所成功完成。
Zimmer Biomet also received U.S. FDA 510(k) clearance for the Z1 Femoral Hip Stem, which is expected to launch later this year.
Zimmer Biomet还获得了美国食品药品管理局的510（k）许可，该产品预计将于今年晚些时候上市。
Outlook: The company reiterated adjusted diluted EPS for FY24 of $8-$8.15 versus the street view of $8.06.
展望：该公司重申24财年调整后的摊薄每股收益为8-8.15美元，而街景为8.06美元。
Zimmer Biomet expects Constant currency revenue change for FY24 in the range of 5%-6%.
Zimmer Biomet预计，24财年的货币收入将持续变化在5％-6％之间。
Price Action: ZBH shares are trading lower by 1.16% to $118.18 at last check Thursday.
价格走势：周四最后一次检查时，ZBH股价下跌1.16％，至118.18美元。
Photo via Wikimedia Commons
照片来自维基共享资源
译文内容由第三方软件翻译。